Stereotactic Radioablation for Ventricular Tachycardia in the Setting of Electrical Storm.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 9 9 2022
medline: 24 9 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

Stereotactic body radiotherapy (SBRT) has been reported as a safe and efficient therapy for treating refractory ventricular tachycardia (VT) despite optimal medical treatment and catheter ablation. However, data on the use of SBRT in patients with electrical storm (ES) is lacking. The aim of this study was to assess the clinical outcomes associated with SBRT in the context of ES. This retrospective study included patients who underwent SBRT in the context of ES from March 2020 to March 2021 in one tertiary center (CHU Lille). The target volume was delineated according to a predefined workflow. The efficacy was assessed with the following end points: sustained VT recurrence, VT reduced with antitachycardia pacing, and implantable cardioverter defibrillator shock. Seventeen patients underwent SBRT to treat refractory VT in the context of ES (mean 67±12.8 age, 59% presenting ischemic heart disease, mean left ventricular ejection fraction: 33.7± 9.7%). Five patients presented with ES related to incessant VT. Among these 5 patients, the time to effectiveness ranged from 1 to 7 weeks after SBRT. In the 12 remaining patients, VT recurrences occurred in 7 patients during the first 6 weeks following SBRT. After a median 12.5 (10.5-17.8) months follow-up, a significant reduction of the VT burden was observed beyond 6 weeks (-91% [95% CI, 78-103]), SBRT is associated with a significant reduction of the VT burden in the event of an ES; however, prospective randomized control trials are needed. In patients without incessant VT, recurrences are observed in half of patients during the first 6 weeks. VT tolerance and implantable cardioverter defibrillator programming adjustments should be integrated as part of an action plan defined before SBRT for each patient.

Sections du résumé

BACKGROUND
Stereotactic body radiotherapy (SBRT) has been reported as a safe and efficient therapy for treating refractory ventricular tachycardia (VT) despite optimal medical treatment and catheter ablation. However, data on the use of SBRT in patients with electrical storm (ES) is lacking. The aim of this study was to assess the clinical outcomes associated with SBRT in the context of ES.
METHODS
This retrospective study included patients who underwent SBRT in the context of ES from March 2020 to March 2021 in one tertiary center (CHU Lille). The target volume was delineated according to a predefined workflow. The efficacy was assessed with the following end points: sustained VT recurrence, VT reduced with antitachycardia pacing, and implantable cardioverter defibrillator shock.
RESULTS
Seventeen patients underwent SBRT to treat refractory VT in the context of ES (mean 67±12.8 age, 59% presenting ischemic heart disease, mean left ventricular ejection fraction: 33.7± 9.7%). Five patients presented with ES related to incessant VT. Among these 5 patients, the time to effectiveness ranged from 1 to 7 weeks after SBRT. In the 12 remaining patients, VT recurrences occurred in 7 patients during the first 6 weeks following SBRT. After a median 12.5 (10.5-17.8) months follow-up, a significant reduction of the VT burden was observed beyond 6 weeks (-91% [95% CI, 78-103]),
CONCLUSIONS
SBRT is associated with a significant reduction of the VT burden in the event of an ES; however, prospective randomized control trials are needed. In patients without incessant VT, recurrences are observed in half of patients during the first 6 weeks. VT tolerance and implantable cardioverter defibrillator programming adjustments should be integrated as part of an action plan defined before SBRT for each patient.

Identifiants

pubmed: 36074658
doi: 10.1161/CIRCEP.122.010955
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010955

Auteurs

Sandro Ninni (S)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Thomas Gallot-Lavallée (T)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Cédric Klein (C)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Benjamin Longère (B)

Department of Radiology (B.L., F.P.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

François Brigadeau (F)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Charlotte Potelle (C)

Intensive Care Unit (C.P.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Frederik Crop (F)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).
Medical Physics, Centre Oscar Lambret, Lille, France (F.C., E.R., C.D., T.L.).

Erwann Rault (E)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).
Medical Physics, Centre Oscar Lambret, Lille, France (F.C., E.R., C.D., T.L.).

Camille Decoene (C)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).
Medical Physics, Centre Oscar Lambret, Lille, France (F.C., E.R., C.D., T.L.).

Thomas Lacornerie (T)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).
Medical Physics, Centre Oscar Lambret, Lille, France (F.C., E.R., C.D., T.L.).

Séverine Lals (S)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).

Claude Kouakam (C)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

François Pontana (F)

Department of Radiology (B.L., F.P.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Dominique Lacroix (D)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Didier Klug (D)

Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.

Xavier Mirabel (X)

University Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center (F.C., E.R., C.D., T.L., S.L., X.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH